A Randomized, Double-Blind Study to Investigate the Effect of aleglitazar [R1439] on Glycemic Control in Patients With Type 2 Diabetes Mellitus.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Aug 2010 Pharmacodynamic outcomes were reported at the ESC Congress 2010: Annual Congress of the European Society of Cardiology.
14 Nov 2009 Results of an exploratory analysis on the effects of aleglitazar on cardiovascular markers has been published as an abstract in the proceedings from the 82nd Annual Scientific Sessions of the American Heart Association (AHA).
09 Jun 2009 Results reported at American Diabetes Assocation meeting (ADA 2009), according to a Roche media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com